Re-evaluation of CKD Stage 2 Diagnosis

Diagnostic Requirements and Considerations

The American Diabetes Association recommends that CKD Stage 1 and Stage 2 are specifically defined by evidence of high albuminuria (UACR ≥30 mg/g) with eGFR ≥60 mL/min/1.73 m², as stated in Diabetes Care 1, 2, 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that when creatinine-based eGFR is 45-59 mL/min/1.73 m² without albuminuria, measuring cystatin C is recommended because persons with both eGFR creatinine and eGFR cystatin C values >60 mL/min/1.73 m² have very low risk for CKD complications and could be considered not to have CKD, as published in the American Journal of Kidney Diseases 4
The combination of both creatinine and cystatin C markers provides a more precise estimate of GFR than either alone, according to the American Journal of Kidney Diseases 4
Biological variability means that eGFR can fluctuate by >20% between measurements even in stable individuals, highlighting the importance of multiple measurements over time, as noted in Diabetes Care 1

The presence of consistently normal UACR results over 2 years is strong evidence against CKD, and patients with mildly reduced eGFR without any evidence of kidney damage may not meet criteria for CKD and carry very low risk for complications, as suggested by the American Journal of Kidney Diseases 4
The American Diabetes Association recommends that at least 2 of 3 specimens should be abnormal to confirm albuminuria, as stated in Diabetes Care 1

The American Diabetes Association recommends that CKD be diagnosed based on persistence of abnormalities for at least 3 months, defined by either eGFR <60 mL/min/1.73 m² or evidence of kidney damage, such as albuminuria with UACR ≥30 mg/g, persisting for ≥3 months 5, 6, 7
The diagnosis of CKD requires confirmation of chronicity by repeating eGFR measurements at least 3 months apart to document persistent eGFR <60 mL/min/1.73 m² 5, 6, 8
Documented kidney damage through albuminuria testing, with two of three UACR specimens collected within 3-6 months being abnormal (≥30 mg/g), is essential for confirming albuminuria 5, 6, 7

The American Diabetes Association suggests that patients with eGFR measurements in the 50s should have repeat testing at least 3 months later to confirm chronicity 5, 6, 8
UACR testing should be performed on at least two occasions, as this is essential for both diagnosis and risk stratification 5, 6
Cystatin C-based eGFR may be considered if there's uncertainty, as creatinine-based eGFR can be affected by muscle mass, diet, and other non-kidney factors 8

The American Diabetes Association warns that diagnosing CKD based on a single eGFR measurement or mild eGFR reduction without confirming chronicity or documenting kidney damage is a common clinical pitfall 5, 6
An eGFR in the 60s with normal uACR and no other kidney damage markers does not constitute CKD 5, 6